title: Oral administration of a synthetic trypsin inhibitor increases pancreatic duct function in CCK-A receptor-deficient rats.
abstract: The effects of oral administration of a synthetic trypsin inhibitor on bicarbonate secretion were examined in cholecystokinin A (CCK-A) receptor-deficient (OLETF) rats and compared with Wistar rats. Rats were fed chow containing 0.1% trypsin inhibitor for 7 days. Rats were prepared with cannulae draining bile and pancreatic juice separately and with duodenal and extrajugular vein cannulae after 3-day trypsin inhibitor ingestion. Then the animals were maintained in Bollman cages, and the experiments were conducted 4 days after surgery. After 1.5 h of basal secretion with bile-pancreatic juice return, bile-pancreatic juice was diverted for 2 h. The responses of bicarbonate secretion to bile-pancreatic juice diversion were significantly enhanced in rats treated with trypsin inhibitor compared with those given a control diet, whereas responses of fluid and protein secretion were not affected in OLETF rats. The response of protein secretion, but not those of fluid or bicarbonate secretion, was enhanced in Wistar rats by treatment with trypsin inhibitor. Carbonic anhydrase II gene expression was increased by 7-day treatment with trypsin inhibitor only in OLETF rats, and not in Wistar rats.
authors.affiliation: Department of Gastroenterology, National Kyushu Cancer Center, Fukuoka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kawanami
authors.forename: A
authors.initials: A
authors.lastname: Funakoshi
authors.forename: S
authors.initials: S
authors.lastname: Suzuki
authors.forename: S
authors.initials: S
authors.lastname: Kanai
authors.forename: Y
authors.initials: Y
authors.lastname: Sato
authors.forename: K
authors.initials: K
authors.lastname: Miyasaka
mesh_terms: D000501:Allylglycine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D001550:Benzamidines / Q000008:administration & dosage / Q000494:pharmacology*; D001639:Bicarbonates / Q000378:metabolism; D001646:Bile / Q000502:physiology; D002256:Carbonic Anhydrases / Q000235:genetics; D002766:Cholecystokinin / Q000097:blood; D007700:Kinetics; D008297:Male; D010179:Pancreas / Q000201:enzymology / Q000378:metabolism; D010183:Pancreatic Ducts / Q000187:drug effects* / Q000502:physiology*; D010189:Pancreatic Juice / Q000502:physiology; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin / Q000172:deficiency*; D014361:Trypsin Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D001550:Benzamidines; D001639:Bicarbonates; D012333:RNA, Messenger; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin; D014361:Trypsin Inhibitors; C100807:ethyl N-allyl-N-(2-methyl-3-(4-(4-amidinophenoxycarbonyl)phenyl)propenoyl)aminoacetate methanesulfonate; D000501:Allylglycine; D002766:Cholecystokinin; D002256:Carbonic Anhydrases